ELREXFIO

(Elranatamab-bcmm)

Phase 2Biologic

AAzienda U.S.L. 1 di Massa e Carrara

ELREXFIO is one of 25 biologic programs targeting Multiple Myeloma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaActive, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Prolia

Amgen

Preclinical

5 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 5

Adriamycin

GGynecologic Oncology Group

Preclinical

9 6

Nolvadex

AstraZeneca

Preclinical

1 7

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 8

ELREXFIO

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

1 9

Intron a

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Recruiting

Multiple Myeloma

NCT07454382

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07454382·26 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 14, 2023

ELREXFIO

BLA BLA761345

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Elranatamab-bcmm. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Elranatamab-bcmm compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Elranatamab-bcmm. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761345). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Azienda U.S.L. 1 di Massa e Carrara company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AAzienda U.S.L. 1 di Massa e Carrara

ELREXFIO

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Multiple Myeloma1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News